TY - JOUR
T1 - Occurrence of premature battery depletion in a large multicentre registry of subcutaneous cardioverter-defibrillator patients
AU - Wörmann, Jonas
AU - Strik, Marc
AU - Jurisic, Stjepan
AU - Stout, Kara
AU - Elrefai, Mohamed
AU - Becher, Nina
AU - Schaer, Beat
AU - van Stipdonk, Antonius
AU - Srinivasan, Neil T
AU - Ploux, Sylvain
AU - Breitenstein, Alexander
AU - Kron, Jordana
AU - Roberts, Paul R
AU - Toennis, Tobias
AU - Linz, Dominik
AU - Dulai, Rajdip
AU - Hermes-Laufer, Julia
AU - Koneru, Jay
AU - Erküner, Ömer
AU - Dittrich, Sebastian
AU - van den Bruck, Jan-Hendrik
AU - Schipper, Jan-Hendrik
AU - Sultan, Arian
AU - Rosenberger, Kerstin D
AU - Steven, Daniel
AU - Lüker, Jakob
PY - 2024/6/17
Y1 - 2024/6/17
N2 - Aims Subcutaneous implantable cardioverter-defibrillators (S-ICDs) have become established in preventing sudden cardiac death, with some advantages over transvenous defibrillator systems, including a lower incidence of lead failures. Despite technological advancements, S-ICD carriers may suffer from significant complications, such as premature battery depletion (PBD), that led to an advisory for nearly 40 000 patients. This multicentre study evaluated the incidence of PBD in a large set of S-ICD patients. Methods Data from patients implanted with S-ICD models A209 and A219 between October 2012 and July 2023 across nine centres in and results Europe and the USA were reviewed. Incidence and implications of PBD, defined as clinically observed sudden drop in battery longevity, were analysed and compared to PBD with the definition of battery depletion within 60 months. Prospectively collected clinical data were obtained retrospectively from medical records, device telemetry, and manufacturer reports. This registry is listed on ClinicalTrials.gov (NCT05713708). Of the 1112 S-ICD devices analysed, 547 (49.2%) were equipped with a potentially affected capacitor linked to PBD occurrence, currently under Food and Drug Administration advisory. The median follow-up time for all patients was 46 [inter-quartile range (IQR) 24–63] months. Clinically suspected PBD was observed in 159 (29.1%) of cases, with a median time to generator removal or replacement of 65 (IQR 55–72) months, indicative of significant deviations from expected battery lifespan. Manufacturer confirmation of PBD was made in 91.7% of devices returned for analysis. No cases of PBD were observed in devices that were not under advisory. Conclusion This manufacturer-independent analysis highlights a notable incidence of PBD in patients equipped with S-ICD models under advisory, and the rate of PBD in this study corresponds to the rate currently estimated by the manufacturer. To the best of our knowledge, this provides the largest contemporary peer-reviewed study cohort investigating the actual incidence of PBD in S-ICD patients. These findings emphasize the importance of post-market registries in collaboration between clinicians and the manufacturer to optimize safety and efficacy in S-ICD treatment.
AB - Aims Subcutaneous implantable cardioverter-defibrillators (S-ICDs) have become established in preventing sudden cardiac death, with some advantages over transvenous defibrillator systems, including a lower incidence of lead failures. Despite technological advancements, S-ICD carriers may suffer from significant complications, such as premature battery depletion (PBD), that led to an advisory for nearly 40 000 patients. This multicentre study evaluated the incidence of PBD in a large set of S-ICD patients. Methods Data from patients implanted with S-ICD models A209 and A219 between October 2012 and July 2023 across nine centres in and results Europe and the USA were reviewed. Incidence and implications of PBD, defined as clinically observed sudden drop in battery longevity, were analysed and compared to PBD with the definition of battery depletion within 60 months. Prospectively collected clinical data were obtained retrospectively from medical records, device telemetry, and manufacturer reports. This registry is listed on ClinicalTrials.gov (NCT05713708). Of the 1112 S-ICD devices analysed, 547 (49.2%) were equipped with a potentially affected capacitor linked to PBD occurrence, currently under Food and Drug Administration advisory. The median follow-up time for all patients was 46 [inter-quartile range (IQR) 24–63] months. Clinically suspected PBD was observed in 159 (29.1%) of cases, with a median time to generator removal or replacement of 65 (IQR 55–72) months, indicative of significant deviations from expected battery lifespan. Manufacturer confirmation of PBD was made in 91.7% of devices returned for analysis. No cases of PBD were observed in devices that were not under advisory. Conclusion This manufacturer-independent analysis highlights a notable incidence of PBD in patients equipped with S-ICD models under advisory, and the rate of PBD in this study corresponds to the rate currently estimated by the manufacturer. To the best of our knowledge, this provides the largest contemporary peer-reviewed study cohort investigating the actual incidence of PBD in S-ICD patients. These findings emphasize the importance of post-market registries in collaboration between clinicians and the manufacturer to optimize safety and efficacy in S-ICD treatment.
KW - Battery Depletion
KW - Device Malfunction
KW - Multicenter Registry
KW - Premature Battery Depletion
KW - S-ICD
KW - Subcutaneous Implantable Cardioverter-Defibrillator
U2 - 10.1093/europace/euae170
DO - 10.1093/europace/euae170
M3 - Article
SN - 1099-5129
VL - 26
JO - EP Europace
JF - EP Europace
IS - 7
M1 - euae170
ER -